FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379650180> ?p ?o ?g. }

• W4379650180 endingPage "1330" @default.
• W4379650180 startingPage "1330.1" @default.
• W4379650180 abstract "Background Patients with rheumatoid arthritis (RA) have increased morbidity and mortality due to cardiovascular (CV) comorbidities. Objectives The association of CV diseases (CVD) and traditional CV risk factors have been debated, depending on patient and RA characteristics. This study aimed to find the prevalence of CVD and CV risk factors in patients with RA. Methods A multi-center cross-sectional study was performed on RA patients using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry). Socio-demographic, clinical, and follow-up data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. Prevalence rates of CVD and traditional CV risk factors were the primary outcomes. Secondary outcomes were the differences in the clinical characteristics between patients with and without CVD. Results We analyzed 724 RA patients with a mean age of 55.1 ±12.8 years. There was a female preponderance (79.6%). The prevalence rate of CVD was 4.6% (n=33). The frequencies of the diseases in the MACE category were ischemic heart disease in 27, congestive heart failure in 5, peripheral vascular disorders in 3, and cerebrovascular events in 3 patients. The patients with CVD (Group 1) were significantly male, older, and had higher BMI (p=0.027, p<0.001, and p=0.041). Obesity (33.4%) and hypertension (27.2%) were the two CV risk factors most frequently. Male sex (HR=0.085, 95% CI:0.028-0.257, p<0.001) and hypertension (HR=4.63, 95% CI:1.251-17.134, p=0.022) were the independent risk factors for CVD. Conclusion The prevalence of CVD in RA patients was 4.6%. Some common risk factors for CVD in the general population, including male sex, older age, and hypertension, were evident in RA patients. sex and hypertension were the independent risk factors for developing CVD in patients with RA. References [1] Raj R, Thomas S, Gorantla V. Accelerated atherosclerosis in rheumatoid arthritis: a systematic review. F1000Res. 2022;11:466. [2] Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82(1):119-129. Table 1. Socio-demographic and clinical characteristics of the study groups. Overall (n=724) Group 1 (n=33) Group 2 (n=691) p Age group ‡ <40 years 92 (12.7) 0 (0) 92 (13.3) 0.015 ≥40 years 632 (87.3) 33 (100) 599 (86.7) Sex ‡ Male 148 (20.4) 12 (36.4) 136 (19.7) 0.027 Female 576 (79.6) 21 (63.6) 555 (80.3) BMI group ‡ <30 kg/m 2 482 (66.6) 17 (51.5) 465 (67.3) 0.087 ≥30 kg/m 2 242 (33.4) 16 (48.5) 226 (32.7) Smoking ‡ Current smoker 101 (14.1) 1 (3.0) 100 (14.7) 0.071 Alcohol ‡ Current consumer 21 (3.0) 2 (6.3) 19 (2.8) 0.248 Educational status ‡ Illiterate/primary 448 (61.9) 22 (66.7) 426 (61.6) 0.865 High school 202 (27.9) 9 (27.3) 193 (27.9) University or higher 73 (10.1) 2 (6.1) 71 (10.3) Comorbidities ‡ Hypertension 197 (27.2) 22 (66.7) 175 (26.6) <0.001 Diabetes mellitus 100 (13.8) 12 (36.4) 88 (13.7) 0.001 Chronic renal failure 23 (3.2) 5 (15.2) 18 (2.9) 0.004 Dyslipidemia 61 (8.4) 11 (44.0) 50 (11.9) <0.001 COPD 39 (5.4) 6 (18.2) 33 (4.8) 0.007 Coagulopathy 6 (0.8) 3 (10.3) 3 (0.5) 0.002 Malignancy 12 (1.7) 2 (6.3) 10 (1.6) 0.113 Valvular heart disease 11 (1.5) 2 (6.1) 9 (1.3) 0.256 † : median (min-max), ‡ : n (%) Group 1 and 2: Patients with and without major adverse cardiovascular event (cardiovascular disease). BMI: body mass index, COPD: chronic obstructive pulmonary disease. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379650180 created "2023-06-08" @default.
• W4379650180 creator A5010943093 @default.
• W4379650180 creator A5014019910 @default.
• W4379650180 creator A5021862949 @default.
• W4379650180 creator A5029104376 @default.
• W4379650180 creator A5032811404 @default.
• W4379650180 creator A5033930616 @default.
• W4379650180 creator A5035817129 @default.
• W4379650180 creator A5038176215 @default.
• W4379650180 creator A5054119053 @default.
• W4379650180 creator A5066579802 @default.
• W4379650180 creator A5069660954 @default.
• W4379650180 creator A5079057678 @default.
• W4379650180 creator A5079535850 @default.
• W4379650180 creator A5086444682 @default.
• W4379650180 creator A5089813564 @default.
• W4379650180 date "2023-05-30" @default.
• W4379650180 modified "2023-10-03" @default.
• W4379650180 title "AB0295 PREVALENCE OF CARDIOVASCULAR DISEASES AND TRADITIONAL CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS:A REAL-LIFE EVIDENCE FROM BIOSTAR NATIONWIDE REGISTRY" @default.
• W4379650180 doi "https://doi.org/10.1136/annrheumdis-2023-eular.2103" @default.
• W4379650180 hasPublicationYear "2023" @default.
• W4379650180 type Work @default.
• W4379650180 citedByCount "0" @default.
• W4379650180 crossrefType "journal-article" @default.
• W4379650180 hasAuthorship W4379650180A5010943093 @default.
• W4379650180 hasAuthorship W4379650180A5014019910 @default.
• W4379650180 hasAuthorship W4379650180A5021862949 @default.
• W4379650180 hasAuthorship W4379650180A5029104376 @default.
• W4379650180 hasAuthorship W4379650180A5032811404 @default.
• W4379650180 hasAuthorship W4379650180A5033930616 @default.
• W4379650180 hasAuthorship W4379650180A5035817129 @default.
• W4379650180 hasAuthorship W4379650180A5038176215 @default.
• W4379650180 hasAuthorship W4379650180A5054119053 @default.
• W4379650180 hasAuthorship W4379650180A5066579802 @default.
• W4379650180 hasAuthorship W4379650180A5069660954 @default.
• W4379650180 hasAuthorship W4379650180A5079057678 @default.
• W4379650180 hasAuthorship W4379650180A5079535850 @default.
• W4379650180 hasAuthorship W4379650180A5086444682 @default.
• W4379650180 hasAuthorship W4379650180A5089813564 @default.
• W4379650180 hasBestOaLocation W43796501801 @default.
• W4379650180 hasConcept C126322002 @default.
• W4379650180 hasConcept C2777575956 @default.
• W4379650180 hasConcept C2778198053 @default.
• W4379650180 hasConcept C2779134260 @default.
• W4379650180 hasConcept C2780400711 @default.
• W4379650180 hasConcept C2780739214 @default.
• W4379650180 hasConcept C500558357 @default.
• W4379650180 hasConcept C511355011 @default.
• W4379650180 hasConcept C71924100 @default.
• W4379650180 hasConceptScore W4379650180C126322002 @default.
• W4379650180 hasConceptScore W4379650180C2777575956 @default.
• W4379650180 hasConceptScore W4379650180C2778198053 @default.
• W4379650180 hasConceptScore W4379650180C2779134260 @default.
• W4379650180 hasConceptScore W4379650180C2780400711 @default.
• W4379650180 hasConceptScore W4379650180C2780739214 @default.
• W4379650180 hasConceptScore W4379650180C500558357 @default.
• W4379650180 hasConceptScore W4379650180C511355011 @default.
• W4379650180 hasConceptScore W4379650180C71924100 @default.
• W4379650180 hasIssue "Suppl 1" @default.
• W4379650180 hasLocation W43796501801 @default.
• W4379650180 hasOpenAccess W4379650180 @default.
• W4379650180 hasPrimaryLocation W43796501801 @default.
• W4379650180 hasRelatedWork W2041279917 @default.
• W4379650180 hasRelatedWork W2082406232 @default.
• W4379650180 hasRelatedWork W2156283049 @default.
• W4379650180 hasRelatedWork W2316954211 @default.
• W4379650180 hasRelatedWork W2326094713 @default.
• W4379650180 hasRelatedWork W2427075784 @default.
• W4379650180 hasRelatedWork W2427452099 @default.
• W4379650180 hasRelatedWork W2617939361 @default.
• W4379650180 hasRelatedWork W2761967325 @default.
• W4379650180 hasRelatedWork W4245782456 @default.
• W4379650180 hasVolume "82" @default.
• W4379650180 isParatext "false" @default.
• W4379650180 isRetracted "false" @default.
• W4379650180 workType "article" @default.